{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:24:50Z","timestamp":1787235890269,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Laser photocoagulation and\/or intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections constitute the current standard treatment for retinopathy of prematurity (ROP). This systematic review and meta-analysis aimed to assess the efficacy and safety of anti-VEGF monotherapy for ROP treatment using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched the Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases. We included randomized controlled trials (RCTs) that compared intravitreal anti-VEGF monotherapy (e.g., bevacizumab, ranibizumab, aflibercept, and pegaptanib) with laser photocoagulation in preterm infants with ROP. We evaluated the rates of recurrence, treatment switching, retreatment, adverse events, and mortality. The risk ratio (RR) was used to represent dichotomous outcomes. Data were pooled using the inverse variance weighting method. The quality of evidence was assessed using the GRADE approach. Risk of bias was assessed using the Revised Cochrane risk of bias tool for randomized trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven RCTs (\n                      <jats:italic>n<\/jats:italic>\n                      = 579; 1,158 eyes) were deemed eligible. Three RCTs had an overall low risk of bias, three had some concerns, and one had an overall high risk of bias. The pooled effect estimate showed a statistically significant reduction in adverse events in favor of anti-VEGF monotherapy [RR = 0.17, 95% confidence interval (CI) 0.07\u20130.44]. The pooled analysis showed no significant difference between the anti-VEGF and laser groups in terms of recurrence rate (RR = 1.56, 95% CI 0.23\u201310.54), treatment switching (RR = 2.92, 95% CI 0.40\u201321.05), retreatment (RR = 1.56, 95% CI 0.35\u20136.96), and mortality rate (RR = 1.28, 95% CI 0.48\u20133.41).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, intravitreal anti-VEGF monotherapy was associated with fewer adverse events than laser therapy, rated as high quality of evidence according to the GRADE criteria. Pooled analysis revealed no significant difference between the two arms with respect to the recurrence rate, treatment switching, retreatment, and mortality rate, with quality of evidence ranging from moderate to very low as per the GRADE approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/#recordDetails<\/jats:ext-link>\n                      ], identifier [CRD42021270077].\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.884608","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:57:58Z","timestamp":1652057878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Nada O.","family":"Taher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Ghaddaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Al-Ghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumanah J.","family":"Homsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar J.","family":"Al-Harbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugean K.","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem S.","family":"Almarzouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.","volume":"94","author":"Karkhaneh","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5935\/0004-2749.20180005","article-title":"Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?","volume":"81","author":"Dikci","year":"2018","journal-title":"Arq Bras Oftalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: a meta-analysis of 3,701 eyes.","volume":"66","author":"Popovic","year":"2021","journal-title":"Surv Ophthalmol."},{"key":"B5","year":"2022","journal-title":"Consultation on Treating Retinopathy of Prematurity in the UK."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0225643","DOI":"10.1371\/journal.pone.0225643","article-title":"Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review.","volume":"14","author":"Tan","year":"2019","journal-title":"PLoS One."},{"key":"B7","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"536.e","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity.","volume":"148","author":"Micieli","year":"2009","journal-title":"Am J Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/j.1755-3768.2012.02552.x","article-title":"What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity.","volume":"91","author":"Spandau","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/s0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol."},{"key":"B13","first-page":"355","article-title":"Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up.","volume":"109","author":"O\u2019Keeffe","year":"2016","journal-title":"Ir Med J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.joco.2018.10.008","article-title":"Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity.","volume":"31","author":"Roohipoor","year":"2019","journal-title":"J Curr Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children.","volume":"42","author":"Kabata\u015f","year":"2017","journal-title":"Curr Eye Res."},{"key":"B18","first-page":"285","article-title":"Anti-VEGF and laser therapy for type 1 retinopathy of prematurity: a meta analysis.","volume":"12","author":"Xiong","year":"2021","journal-title":"Int Eye Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American academy of ophthalmology.","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","article-title":"Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity \u2014 27 month follow-up results from Turkey.","volume":"253","author":"Yetik","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jaapos.2021.02.004","article-title":"Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report.","volume":"25","author":"Taylor","year":"2021","journal-title":"J AAPOS."},{"key":"B22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tjo.2012.10.001","article-title":"Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity: a preliminary report.","volume":"2","author":"Lin","year":"2012","journal-title":"Taiwan J Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","article-title":"Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity.","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.jaapos.2018.07.132","article-title":"Retreatment of retinopathy of prematurity after primary intravitreal bevacizumab montherapy.","volume":"22","author":"Helmy","year":"2018","journal-title":"JAAPOS."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","article-title":"Intravitreous Bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.","volume":"126","author":"Kong","year":"2008","journal-title":"Arch Ophthalmol."},{"key":"B26","author":"Chiang","year":"2021","journal-title":"International Classification of Retinopathy of Prematurity."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1038\/s41598-021-83985-5","article-title":"Management of retinopathy of prematurity (ROP) in a polish cohort of infants.","volume":"11","author":"Chmielarz-Czarnoci\u0144ska","year":"2021","journal-title":"Sci Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","article-title":"Significant Treatment Failure With intravitreous Bevacizumab for retinopathy of prematurity.","volume":"130","author":"Patel","year":"2012","journal-title":"Arch Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41372-020-00884-9","article-title":"Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis.","volume":"41","author":"Kaushal","year":"2021","journal-title":"J Perinatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab.","volume":"35","author":"Chen","year":"2015","journal-title":"Retina."},{"key":"B33","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br J Ophthalmol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/aos.12604","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.","volume":"93","author":"Zehetner","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"B36","year":"2021","journal-title":"Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity."},{"key":"B37","year":"2021","journal-title":"Open-Label, Randomized, Two-Arm, Controlled Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal (IVT) Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (ROP)."},{"key":"B38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: specific role and optimal use.","volume":"7","author":"Semeraro","year":"2013","journal-title":"Drug Des Devel Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.","volume":"37","author":"Avery","year":"2017","journal-title":"Retina."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.2147\/OPTH.S90979","article-title":"Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity.","volume":"9","author":"Ar\u00e1mbulo","year":"2015","journal-title":"Clin Ophthalmol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"884","DOI":"10.4103\/ijo.ijo_708_18","article-title":"Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity.","volume":"67","author":"Vedantham","year":"2019","journal-title":"Indian J Ophthalmol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.884608\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:58:04Z","timestamp":1652057884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.884608\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":42,"alternative-id":["10.3389\/fmed.2022.884608"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.884608","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"article-number":"884608"}}